PL3548633T3 - Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów - Google Patents
Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworówInfo
- Publication number
- PL3548633T3 PL3548633T3 PL17817030.4T PL17817030T PL3548633T3 PL 3548633 T3 PL3548633 T3 PL 3548633T3 PL 17817030 T PL17817030 T PL 17817030T PL 3548633 T3 PL3548633 T3 PL 3548633T3
- Authority
- PL
- Poland
- Prior art keywords
- chromsomal
- epigenetic
- interactions
- application
- cancer diagnostics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3548633T3 true PL3548633T3 (pl) | 2024-04-02 |
Family
ID=60702831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17817030.4T PL3548633T3 (pl) | 2016-12-01 | 2017-11-30 | Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (enExample) |
| EP (2) | EP4357463A3 (enExample) |
| JP (2) | JP2019535295A (enExample) |
| KR (1) | KR102481242B1 (enExample) |
| CN (1) | CN110234769B (enExample) |
| AU (1) | AU2017367245B2 (enExample) |
| CA (1) | CA3045070A1 (enExample) |
| ES (1) | ES2971286T3 (enExample) |
| MY (1) | MY190153A (enExample) |
| PL (1) | PL3548633T3 (enExample) |
| TW (1) | TWI865427B (enExample) |
| WO (1) | WO2018100381A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225551A1 (en) * | 2019-05-08 | 2020-11-12 | Oxford BioDynamics PLC | Chromosome conformation markers of prostate cancer and lymphoma |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564262A (en) * | 2005-07-04 | 2010-02-26 | Univ Erasmus Medical Ct | Chromosome conformation capture-on-chip (4C) assay |
| GB0603251D0 (en) * | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| AU2008204338B2 (en) * | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
| CA2609172A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Utah Research Foundation | Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| GB0810051D0 (en) * | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| WO2010036323A1 (en) | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
| EP2366162A1 (en) * | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
| CA2804450C (en) * | 2010-07-09 | 2022-10-11 | Max Jan van Min | 3-d genomic region of interest sequencing strategies |
| US20140056898A1 (en) * | 2011-02-24 | 2014-02-27 | Bo Zhang | Combination therapies comprising anti-erbb3 agents |
| EP2710146A2 (en) * | 2011-05-18 | 2014-03-26 | Life Technologies Corporation | Chromosome conformation analysis |
| AU2013280644B2 (en) * | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN102827935B (zh) * | 2012-08-29 | 2013-12-18 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| JP2018518203A (ja) | 2015-06-24 | 2018-07-12 | オックスフォード バイオダイナミックス リミテッド | エピジェネティックな染色体相互作用 |
| EP3390656B1 (en) * | 2015-12-14 | 2020-04-08 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018100381A1 (en) | 2018-06-07 |
| CA3045070A1 (en) | 2018-06-07 |
| TW201842190A (zh) | 2018-12-01 |
| ES2971286T3 (es) | 2024-06-04 |
| TWI865427B (zh) | 2024-12-11 |
| NZ753716A (en) | 2024-05-31 |
| MY190153A (en) | 2022-03-31 |
| KR20190086569A (ko) | 2019-07-22 |
| CN110234769B (zh) | 2024-06-07 |
| US11560597B2 (en) | 2023-01-24 |
| KR102481242B1 (ko) | 2022-12-23 |
| AU2017367245B2 (en) | 2020-09-24 |
| EP3548633B1 (en) | 2024-01-24 |
| JP2023027076A (ja) | 2023-03-01 |
| US20230082230A1 (en) | 2023-03-16 |
| EP4357463A3 (en) | 2024-07-17 |
| EP3548633A1 (en) | 2019-10-09 |
| EP3548633C0 (en) | 2024-01-24 |
| JP7579003B2 (ja) | 2024-11-07 |
| AU2017367245A1 (en) | 2019-06-06 |
| CN110234769A (zh) | 2019-09-13 |
| EP4357463A2 (en) | 2024-04-24 |
| US20190338367A1 (en) | 2019-11-07 |
| JP2019535295A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256025A (en) | Methods of diagnosing and treating cancer | |
| SG11201606193RA (en) | Biomolecule analysis kit and biomolecule analysis method | |
| IL248819A0 (en) | Translation during a conversation | |
| IL252361A0 (en) | Preparations and methods for the treatment and diagnosis of cancers resistant to chemotherapy | |
| GB2545361B (en) | Methods of assessing colorectal cancer status | |
| GB201420859D0 (en) | Tumour analysis | |
| GB201616912D0 (en) | Classification of cancer | |
| GB2543200B (en) | Junction-conveyed completion tooling and operations | |
| GB201608459D0 (en) | Diagnostic methods and kits | |
| GB201618200D0 (en) | Simultaneous analysis of multiple components in well fluids | |
| GB201609600D0 (en) | Cancer treatments | |
| IL267315A (en) | Methods of determining colorectal cancer status in an individual | |
| IL251903B (en) | Epilimod for use in the treatment of colon cancer | |
| SG10201913528PA (en) | Methods of diagnosing cancer | |
| PL3268337T3 (pl) | Sposoby i zestawy do przygotowania kompleksów radionuklidu | |
| SG10201605375YA (en) | Sample holder and sample holder set | |
| GB201608776D0 (en) | Methods and compounds | |
| SG11201700893WA (en) | Biomolecule analyzer | |
| SG10201504344VA (en) | Component processing | |
| PL3548633T3 (pl) | Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów | |
| GB201417661D0 (en) | Agile Software Development Process And Results | |
| GB2557337B (en) | Workbench | |
| PT3298165T (pt) | Método e kit para diagnóstico de cancro colorretal | |
| GB201601585D0 (en) | Cancer | |
| GB201417372D0 (en) | Methods and kits |